Study the Influence of Treatment Interruptions in the Radical Irradiation of Breast Cancer by Azam, Alia A. et al.
I S S N  2 3 4 7 - 3 4 8 7  
V o l u m e  1 3  N u m b e r  5  
J o u r n a l  o f  A d v a n c e s  i n  P h y s i c s  
4858 | P a g e                                        
M a y  2 0 1 7                                                              w w w . c i r w o r l d . c o m  
Study the Influence of Treatment Interruptions in the Radical 
Irradiation of Breast Cancer 
 
Ahmed H. Oraby1, Ibrahim A. Awad2, Ehab M. Attalla3, and Alia A. Azzam4 
1
Department of Physics, Faculty of Science, Mansoura University, Mansoura, Egypt 
2




Department of Physics, Division of Medical Physics, National Cancer Institute, Cairo University & 
Children's Cancer Hospital, Cairo, Egypt 
attalla.ehab@gmail.com 
       4





Purpose:   Hypofractionated   radiotherapy   (HFRT)   in breast cancer treatment regimen (40 Grey /15 fractions/3 weeks) 
is more convenient for patients, especially those coming from remote areas to radiotherapy facilities and for healthcare 
providers, than conventional fractionation (50 Gy/25 fractions/5weeks). So the effect of radiotherapy interruption on 
treatment outcome (loco-regional control (LRC)& overall survival (OS)) during hypofractionated schedule is the issue of 
our study. 
Materials and Methods: We studied retrospectively 174 female patients with breast cancer who received PORT at the 
Clinical Oncology & Nuclear Medicine Department, Faculty of Medicine, Mansoura University, Egypt, from January-2012  
to December-2016. We determined the treatment outcome (OS&LRC) from the follow-up (FU) of the studied patients, as 
the patient still survived or died, and recurrence till now occurred or not, and were estimated with the Kaplan-Meier   (K-
M) method and Logrank test, respectively. Then we calculated surviving fraction (SF) and tumor control probability (TCP) 
with regard to biologically effective dose (BED), for all patients, using breast cancer radiobiological parameters. 
Results: When comparing patients without radiotherapy gap with patients with radiotherapy gaps, the results showed a 
decrease in LRC rate in patients with radiotherapy treatment interruptions by 15 % (P=0.019, a significant value), but no 
detrimental effect on OS because of the very limited number of the studied patients. Curves of the relationship between 
(SF&OTT) and (TCP&OTT) confirmed the detrimental effect of unscheduled gap during radiotherapy fractions on the 
treatment outcome. Also we found a significant-P value for (marital status, start day of radiotherapy fractions, time, 
number, and duration of gaps); it means these factors affect LRC during radiotherapy interruptions. 
Conclusion: Interruptions during postoperative hypofractionated irradiation of breast cancer (40 Gy/15 fractions/3weeks) 
should be avoided and if they are inevitable, they should not be prolonged more than two days, as they will adversely 
affect the treatment outcome (LRC).  
Keywords: PORT: Post-Operative Radiotherapy, OTT: Overall Treatment Time, LR: Local Recurrence, HFRT: 
Hypofractionated radiotherapy, LRC: Loco-Regional Control, OS: Overall Survival, FU: Follow-Up, K-M: Kaplan-Meier, SF: 
Surviving Fraction, TCP: Tumor Control Probability, BED: Biologically Effective Dose, BCS: Breast Conserving Surgery, 
NACT: Neoadjuvant Chemotherapy, and PMRT: Postmastectomy Radiotherapy.] 
1.INTRODUCTION 
       Worldwide, breast cancer is the most common cancer among females [1]. Treatment of breast cancer includes 
surgical intervention, radiotherapy (RT), and systemic treatment with cytotoxic chemotherapy (CT), hormone therapy, 
targeted (biologic) therapy, or a combination of these [2, 3]. Radiation after breast conserving surgery (BCS) for early as 
well as locally advanced tumor after neoadjuvant chemotherapy (NACT) is now considered as an integral part of Breast 
Conserving Therapy (BCT) whereas postmastectomy radiotherapy (PMRT) to chest wall and or regional area is 
considered beneficial for a selected group of high risk patients [4-9]. PMRT  decreases loco-regional recurrence (LRR) in 
women with operable breast cancer and inhances survival [10]. 
   Conventional fractionated radiotherapy has been limited by patient’s compliance, travelling, unplanned interruption and 
others. Hypofractionated schedule would be more appealing and convenient [10]. In the clinical practice, daily, unplanned 
radiotherapy interruptions are inevitable because of intercurrent disease, acute radiation reactions, machine breakdowns, 
public holidays, and patient non-compliance [11]. Good clinical Practice (to achieve tumor control) dictates that radical 
courses of radiotherapy treatment should not be interrupted. Where this is not possible, compensatory treatment is 
required [12]. 
    Recently it had been shown that radiotherapy interruptions lasting more than a week decreased LRC and OS (patient 
outcomes) rates in breast cancer patients treated with postoperative radiotherapy (PORT) after breast-conserving surgery 
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and mastectomy [11, 13]. But there are no reports for the effect of unscheduled treatment gaps in the radical irradiation of 
breast cancer on patient outcomes, in case of hypofractionation regime (40 Gy per 15 fractions over 3 weeks), thus it will 
be our issue in this study using retrospective analysis. 
2.PATIENTS&METHODS 
2.1.Patients 
       174 female breast cancer patients who received postoperative radiotherapy (in the year 2012 and 2013 inclusive), at 
the Clinical Oncology & Nuclear Medicine Department, Faculty of Medicine, Mansoura University, Egypt, were 
retrospectively analyzed. 
       All the studied patients underwent surgery as the primary treatment modality of breast cancer; 21 patients (12.1%) 
underwent breast-conservative surgery while 153 patients (87.9 %) underwent mastectomy. 
2.2.Methods 
2.2.1.Radiotherapy Fractions 
       Irradiation of chest wall or breast was with two tangential medial and lateral beams. irradiation of Lymph nodes 
(supraclavicular, axillary and internal mammary chain) was with an anterior one direct beam at 3 cm depth, or two parallel 
opposed fields (dose to axilla was supplemented with a posterior beam). Patients were irradiated with the linear 
accelerator unit; by 6 MV or 15 MV of the ELEKTA; Precise, 6 MV of the SL75/5 photon beams, or 6, 8, 10, 12, and 15 
electron beams from the ELEKTA; Precise. The choice of the machine and energy type is achieved according to patient 
weight, and (the target volume and depth), respectively. A total dose of 40 Gy (hypofractionated radiation therapy (HFRT)) 
was delivered to the breast or the chest wall and regional lymph nodes in 2. 67 Gy per fraction (5 daily fractions in a week) 
from Saturday to Wednesday; conventional fractionation, according to the treatment tactic of the department. The overall 
treatment time (OTT) was 19 days if the patient started radiotherapy fractions on Saturday, or 21 days if patient started on 
any other day from Sunday to Wednesday.   A 16 Gy (2 Gy daily fraction), or 9 Gy (3Gy weekly fraction) boost dose 
(electron or photon beams) was delivered to tumor bed after breast-conservative surgery. 
2.2.2. Adjuvant Systemic Therapy 
       chemotherapy  or  hormonal  therapy  was  given  to 174 patients (100%). One hundred and twenty-two patients 
(69.7%) received hormonal treatment (tamoxifen). One hundred and seventy-two patients (98.8%) received 
chemotherapy, and 120 patients (68.9%) received chemotherapy and hormonal therapy. Some patients received 
chemotherapy following postoperative irradiation; however, the others finished chemotherapy before irradiation or 
received a few cycles before irradiation (a sandwich regimen). Chemotherapy regimen consisted of: (a) 6 cycles of CMF  
(cyclophosphomide;  methotraxate;  5-fluouracil). (b) Or 6 cycles of CAF or CEF (doxorubicin (A) or epirubicin (E)); an 
anthracycline based regimen. (c) Or 4 cycles of AC or EC (A 60 or E 90). Thirty five patients (20.1 %) with HER2- positive 
breast cancers received targeted therapy (Trastuzumab or Herceptin). Ninety three patients (53.45%) were HER2- 
negative breast cancers, and fourty six cases (26.4%) were unknown. 
 
2.2.3. Determination of Radiotherapy Interruptions 
      Weekends (Thursday and Friday) as they are integral parts of the conventional radiotherapy scheme, Thursdays and 
Fridays were not considered as radiotherapy breaks; however, if the gap was before or after a weekend, Thursday and 
Friday were included in the interruption. In calculation, the total number of  days of interruption was summed and 
processed as weeks.  Unscheduled  radiotherapy  breaks  occurred in 129 patients (74.1%). Among these 129 patients 
the mean and median durations of the gaps were 17 and 13 days, respectively, and range was (1-89 days). For all the 
studied patients (174 patients), including 45 patients without radiotherapy interruption, the mean and median duration of 
the interruptions were 16 and 12 days, respectively. When gaps number was estimated, 51 patients (29.3%) had one 
radiotherapy gap, while 84 patients (48.3%) had more than one treatment gap. In 22 patients (17%) early skin reaction 
was the main cause of interruption. 
    According to the duration of treatment interruptions all the studied patients were distributed into 4 groups. Group (A) 
include 45 patients (25.9%) who had no radiotherapy break. Group (B) include 87 patients (50%) with radiotherapy 
interruptions ≤ 7 days (≤ 1week). Group (C) include 26 patients (14.9%) with radiotherapy gaps ≥ 8 days and ≤ 14 days. 
Group (D) include 16 patients (9.2%) with radiotherapy gaps ≥ 15 days or more. 
 
2.2.4. Radiobiological Calculations 
      To calculate surviving fraction (SF) and tumor control probability (TCP) with regard to biologically effective dose 
(BED), by using breast cancer radiobiological parameters and the following equations:  
BED= n. d [1+ d÷ (α/β)]-K (T-Tdelay) →Eq.  (1) [12, 14-16] 
ln(SF)= -E [17, 18] 
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dividing by α: 
ln(SF)/ α = -E/ α=-BED ln(SF)= -α. BED  
then,  
SF=[exp. (-α. BED)] →Eq. (2) TCP= [exp. (-N0. SF)] 
TCP= {exp. [-N0. exp. (-α. BED)]} →Eq. (3) [15] 
Where: n (the number of well-spaced and identical fractions) =15 fractions, d (the dose per fraction) =2.67 Gy 
(hypofractionation regimen 40 Gy/15 fractions) [16]. (α/β) ratio (is the linear to quadratic coefficients in the linear quadratic 
(LQ) model, and represents the dose at which single and double-hit killing events are equal in number; at higher doses 
double-hit  killing events start  to progressively dominate) = 4 Gy [19]. 
K (tumor repopulation factor) = ln2/ α. Td = 0.693/ α. Td (potential doubling time), Td=13 days, α=0.3 Gy-1 [20, 16]. 
T (overall treatment time) = 19 days or 21 days if the patient started radiotherapy fractions on Saturday or midweek 
respectively [16]. 
Tdelay (the days between the start of radiotherapy and the onset of tumor repopulation) = 14 days [16]. 
N0 (the initial number of clonogens in the tumor) = 109. V [15]. The density of clonogens per cubic centimeter  (cc) =109 
[15]. There is general agreement in the literature that 1 cm3 tumor mass contains, 109 cells [21]. We considered V (actual 
volume of the tumor) = 10-2 cc after surgery for all patients in our study. 
2.2.5. Patients, Data 
      Collect host and treatment-related factors: age, weight, height, marital status, menopausal status, histological types of 
the tumor, grade of the tumor, PT stage and PN stage of the tumor according to the clinical TNM Staging System, start day 
of radiotherapy, time, number, and duration of gaps, and treatment outcomes (overall survival (OS) and loco-regional 
control (LRC)) from the follow-up (FU) of the patient,  as the patient still survived or died, and recurrence till now occurred 
or not. 
2.2.6. Statistical Analysis 
      We  used SPSS Statistical package for social   science. The qualitative data were presented in the form of number and 
percentage. Chi-square used as a test of significance. The quantitative data were presented  in the form of mean and standard 
deviation. Student t test was used for Quantitative data. Correlation was used to study the correlation between data. Kaplan-




      The LRC rate of 45 patients with no radiotherapy gap (group A) for 5 years was (93.3%), and the LRC rate of  129 
patients  with radiotherapy gaps  (groups  B,C +D) was (78.3%) for 5 years. When we compared the patients with 
radiotherapy gaps with the patients without radiotherapy gap, the difference  was statistically significant (p = 0.019) by 









Figure (1): A comparison between group A and groups B, C+D for LRC. 
     We could not observe a detrimental effect of interruptions on OS rates (p=0.81), or the difference between group A and 
groups B, C+D was not statistically significant, and this was due to the very poor number of patients in each group, and 
estimations in larger patient groups would further clarify the hypothesis of the negative effect of decreased LRC on OS; 
table (1). But it has been proven theoretically the  bad effect of interruption on both tumor control probability  (TCP)  and  
surviving  fraction  (SF); figures (2) and (3). 
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      The relationship between tumor control probability (TCP)&overall treatment time (OTT) in days, and between surviving 
fraction (SF)&overall treatment time (OTT) in days, in the comparison between group A and groups B, C+D are shown in 
figures (2) and (3), respectively by correlation. In figure (2), the slope of the curve expressed  in groups B, C+D increased 
down after 19 days (the overall treatment time with not-interrupted radiotherapy fractions or compliant radiotherapy). The 
curve expressed in groups B, C+D shows a decreased TCP (measured in %) with increased OTT in days, and the curve  
expressed in group  A shows the higher TCP (measured in %) with the overall treatment time 19 days (the compliant 
radiotherapy course). 
 
            
Figure (2): Relationship between OTT & TCP. 
 
In figure (3), the slope of the curve expressed in groups B, C+D increased up after 19 days (compliant radiotherapy 
course). The curve expressed in groups B, C+D shows an increased SF (measured in number of surviving cells) with 
increased OTT (in days), and the curve expressed in group A shows the lower SF (measured in number of surviving 
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Figure (3): Relationship between OTT & SF. 
 
      When we compared demographic characteristics of the patients without radiotherapy interruption with the patients with 
radiotherapy breaks, it was found that the distribution of the patients according to marital status was differentially highly 
significant (p=0.001), but it was non- significant for age (p=0.66), weight (p=0.37), height  (p=0.14), menopausal status 
(p=0.92), by Chi-square test as a test of significance; table (2). 
 







































































































     Chi-square test showed that grade, histological type, T stage, and N stage had not significantly influenced LRC 
(p=0.81, p=0.60, p=0.42, and p=0.32 respectively); table (3). 
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Table (3): Influence of histological and pathological factors on LRC in the comparison between group A and 
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     Chi-square test showed that in all the Start day of RT fractions, number of gaps, time of gap, and duration of gap, the 
difference was statistically highly significant (p=0.001), and independently related with LRC; table (4). 
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     Bese N. S. et al. had the first clinical paper evaluated the impact of radiotherapy breaks in postoperative radiotherapy 
of breast cancer during the schedule (50 Gy/25 fractions/5 weeks). They found when the  duration  of radiotherapy 
interruption was prolonged over 7 days, a negative effect was found on both OS and LRC, and the average decrease in 
the LRC rate was 5% along 5-years,  but there were no detrimental impact on patient treatment outcome if the duration of 
gap lasted for period ≤ 1 week [11]. 
     Bese N. S. et al. repeated the previous study on ostoperative irradiation interruptions after breast- onserving Surgery. 
They also found that prolongation of more than one week negatively impact LRC by a 9% ecrease in the 5-year LRC rate 
[13]. 
    Nitin Ohri et al. reviewed all patients who completed ourses of external beam RT with curative intent in their epartment 
from the years 2007 to 2012 for cancers of the ead and neck, breast, lung, cervix, uterus, or rectum. atients  who  missed  
≥  2  days  (excluding  planned eatment breaks) were deemed  noncompliant.  They ported that RT noncompliance was 
associated  with creased recurrence risk, 5-year cumulative incidence 16% ersus 7%, P<0.001 [23]. 
   We have done the first clinical and physical study estimating the impact of radiotherapy gaps in postoperative 
radiotherapy of breast cancer in the  schedule (40 Gy/15 fractions/3 weeks). In our work, we found that no detrimental 
impact on  the  treatment outcome of the patient with duration of gap ≤ 2 days  (as the patients with duration of interruption 
≤ 2 days represents 30% only in groups B; table (4), in addition to those patients are included in group B which have the 
big number of samples 87 (50%) of all the studied patients (all groups A, B, C, and D), which is the major point of 
weakness in our study (sample size is very limited) or the population number is very heterogeneous as it is a retrospective 
study, and the influence of unscheduled interruptions can be shown only if data is analyzed retrospectively. 
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   Figure (1) describes a comparison between group A and groups B, C+D for LRC, in which the green curve represents 
groups B, C+D curved down and more steeper gradually with time. The blue line is straight but at three points because of 
the three recurrence cases in the group. 
   Figure (2) shows the relationship between OTT & calculated TCP, in which the beginning point of the blue line (group A) 
appeared at 19 days, the time of compliant radiotherapy course, the higher point on the green line (groups B, C+D) 
appeared after that and is steeper gradually down to (4%). The mean value of TCP=96% and 95% in groups A and B, 
respectively. 
    Figure (3) shows the relationship between OTT & SF, in which also the beginning point of the blue line (group A) 
appeared at 19 days, the time of compliant radiotherapy course, points on the green line (groups B, C+D) appeared after 
that and is steeper gradually up to 9.85 cells; which is the meaning of surviving cells. The mean value of SF=3.49 and 
3.51 in groups A and B, respectively. 
    From table (2) the marital status had influenced LRC, but the rest factors did not have any influence on LRC. A trial to 
study separately the effect of marital status on LRC and by the radiotherapy interruption, the size of patients, sample is 
small and not enough to estimate the small difference at a significant or non-significant  value;  table (2). In Bese N. S. et 
al., the distribution of the patients according to menopausal status was differentially significant (p=0.04) [11]. 
    From table (3) histological& pathological factors had not significantly influenced treatment outcome.  Bese N.  S.  et al. 
found that there were no significant differences for the distributions of N stage (P= 0.555), T stage (p = 0.984), and the 
adjuvant systemic treatment (p = 0.172). Distribution of patients according to type of surgery when compared with the 
Pearson _ 2 test, was significantly different (p = 0.005) between the two groups [11]. 
   In table (4) the difference was statistically highly significant, and independently related with LRC. This significant value 
leads us to do separate studies to analyze the effect of each factor alone. Major number of the  patients in group A 
(patients without radiotherapy interruptions) started RT at the beginning of the week; 28 patients  (62.2%),  while  a  
higher  percentage of patients in groups with interruption started RT mid-week; 58 patients (45%) (p= 0.001). If the 
patients start radiotherapy fractions on Saturday, the overall treatment time (OTT) will be 19 days, but if they started on 
mid-week, the overall  treatment time (OTT) will be 21 days by adding weekends. It means that starting radiotherapy 
midweek prolonged OTT, and affected LRC. There were detected gaps in group A, 6 patients (13.3%) by a one day, but 
these gaps had been compensated during fractions, either by on weekend or twice fractions in one day with 6 hours apart, 
thus resulted in no prolongation in OTT. 
   In our study, in 22 patients (17%) the reason for interruption was skin reaction early, and in 2 patients (1.6%) treatment 
delay was due to reasons related to medical status of the patients. The other reasons of radiotherapy breaks were public 
holidays, servicing of the machine, machine breakdowns and noncompliance of patient in 105 patients (81.4%). The 
position (time) of the gaps was analyzed, and it was found that the distribution of the patients according to time of gap was 
differentially highly significant (p=0.001), although in 85 patients (66%) the number of radiotherapy interruptions was more 
than one. 
    Bese N. S. et al. reported that the reason for gap in 55% of the patients was early skin reaction and radiotherapy 
treatment delay was due to leukopenia in 9% of the patients. There were no other reasons for the gaps related to medical 
status of the patients were observed. Other causes of gaps were public holidays, breakdowns of machine, servicing of 
machine and noncompliance of patient. The time of the breaks was not analyzed because the number of radiotherapy 
interruptions was more than one in 68% of the patients [11]. 
    It is impossible to prevent some radiotherapy breaks  such as those resulting from a bad clinical response to treatment 
or machine breakdowns, but those  resulting from the public holidays can be preplanned. We have to make great efforts 
to reach the optimized radiotherapy treatment plan to avoid increased doses on skin. Awareness of staff involved in the 
treatment and patients about the rationale and the importance of the radiotherapy gaps is a necessity. There are 
guidelines for compensating for interrupted radiotherapy, the Royal College of Radiologists (RCR), in 2008, published the 
third edition of "Guidelines for the Management of the Unscheduled Interruption or Prolongation of a Radical Course of 
Radiotherapy" to help departments of clinical oncology in producing local protocols for compensation [12]. 
 
4.CONCLUSION 
   We studied the patients retrospectively in this paper, and we found that in the postoperative radiotherapy of breast 
cancer, gaps for more than two days during radiotherapy schedule (40 Gy/15 fractions/3 weeks) had a detrimental effect 
on treatment outcome in term of LRC. 
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